Rheumatology

Latest News

Using Telemedicine Interventions During COVID-19 to Expand Care Post COVID-19

January 24th 2023

The Patient-Centered Rheumatology Collaborative identified several critical areas for further intervention to improve the delivery of high-quality, patient-centered care during the COVID-19 pandemic and beyond.

A graphic with the title and health icons
Top 5 Most-Read Rheumatology Articles of 2022

January 1st 2023

picture of cannabis leaf
Cannabis Improves Quality of Life in Women With Treatment-Resistant Fibromyalgia

December 14th 2022

graphic depicting immune system
Stopping Methotrexate for 1 Week After Flu Vaccine May Work as Well as 2 Weeks

December 1st 2022

Cardiac
Early TNF Inhibitor Initiation in Ankylosing Spondylitis Linked to Increased Cardiovascular Risk

November 15th 2022

More News

Factors Affecting Efficacy of Secukinumab in Psoriatic Arthritis and Axial Spondyloarthritis
July 9th 2020

Factors Affecting Efficacy of Secukinumab in Psoriatic Arthritis and Axial Spondyloarthritis

Laura Joszt, MA
Treatment options for psoriatic arthritis and axial spondyloarthritis are increasing, and with studies already identifying response predictors for tumor necrosis factor inhibitors, there is a need to predict response to the interleukin-17A inhibitor secukinumab.
ACR Position Statement Supports Use of Telemedicine After COVID-19 Crisis
July 3rd 2020

ACR Position Statement Supports Use of Telemedicine After COVID-19 Crisis

Laura Joszt, MA
The coronavirus disease 2019 (COVID-19) public health emergency has led to an increased use of telemedicine services as CMS instituted reimbursement parity with in-person services. In a new position statement, the American College of Rheumatology has stated support for continuing to use telemedicine once the COVID-19 emergency passes.
Addressing the Challenge of Nonadherence in Rheumatic Diseases
July 1st 2020

Addressing the Challenge of Nonadherence in Rheumatic Diseases

Laura Joszt, MA
Among patients with rheumatic diseases, medication nonadherence remains a significant problem because of a lack of standardization and guidance on terminology, measurement, and outcome selection, according to an abstract presented at the European Congress of Rheumatology of the European League Against Rheumatism.
Using Disease Activity Measures to Guide Tapering and Compare Biologics to Treat RA
June 26th 2020

Using Disease Activity Measures to Guide Tapering and Compare Biologics to Treat RA

Laura Joszt, MA
While biologics may have improved outcomes in rheumatoid arthritis (RA), they also have higher costs and adverse events, and patients are more likely to request dose reductions or drug holidays.
Well-being and Medication Necessity Beliefs Among Patients With RA
June 24th 2020

Well-being and Medication Necessity Beliefs Among Patients With RA

Laura Joszt, MA
Despite advances in therapeutics and treatment strategies for rheumatoid arthritis (RA) that impact well-being, patients in clinical remission still report reduced well-being, according to an abstract presented at the European Congress of Rheumatology of the European League Against Rheumatism.
Secukinumab Approved to Treat Nonradiographic Axial Spondyloarthritis Based on Safety, Efficacy of PREVENT
June 19th 2020

Secukinumab Approved to Treat Nonradiographic Axial Spondyloarthritis Based on Safety, Efficacy of PREVENT

Laura Joszt, MA
Based on the safety and efficacy outcomes from the PREVENT phase 3 study, the FDA has approved secukinumab (Cosentyx) from Novartis for the treatment of active nonradiographic axial spondyloarthritis.
Translating Differing Disease Activity Scores Into a Universal Score for Rheumatologists
June 17th 2020

Translating Differing Disease Activity Scores Into a Universal Score for Rheumatologists

Laura Joszt, MA
Measuring disease activity is a key aspect of rheumatologic care, but the creation of tools designed specifically for disease areas of interest has resulted in fragmentation and multiple disease activity scores, sometimes even just for a single disease.
Real-World Results and Long-Term Safety Data for Secukinumab
June 12th 2020

Real-World Results and Long-Term Safety Data for Secukinumab

Laura Joszt, MA
Two abstracts presented at the European Congress of Rheumatology of the European League Against Rheumatism reviewed long-term safety data and real-life effectiveness and safety of secukinumab for ankylosing spondylitis, psoriasis, and psoriatic arthritis.
Earlier Visits More Likely to Result in Sustained DMARD-Free Remission for Patients With RA
June 9th 2020

Earlier Visits More Likely to Result in Sustained DMARD-Free Remission for Patients With RA

Laura Joszt, MA
Recommendations that patients with rheumatoid arthritis see an expert within 6 weeks of symptom onset can provide challenges for practices.
Majority of Patients With Rheumatic Conditions Recover From COVID-19 Regardless of Rheumatic Disease Therapy
June 5th 2020

Majority of Patients With Rheumatic Conditions Recover From COVID-19 Regardless of Rheumatic Disease Therapy

Laura Joszt, MA
Drugs used to treat rheumatic conditions suppress the rogue immune system, but it has been unclear whether patients using immunosuppressants have an increased risk of a more severe course if they are infected with the coronavirus disease 2019 (COVID-19).
Study Highlights Potential Metabolic Targets in Autoimmune Disease
June 3rd 2020

Study Highlights Potential Metabolic Targets in Autoimmune Disease

Jared Kaltwasser
New therapies for autoimmune conditions like rheumatoid arthritis (RA) highlight the potential of metabolic targets. A recent study highlights some of the most promising targets.
Evolving Approaches to Care in the Management of Psoriatic Disease
May 31st 2020

Evolving Approaches to Care in the Management of Psoriatic Disease

An Interview With Erin L. Arnold, MD, FACR
Erin L. Arnold, MD, FACR, of Orthopaedics and Rheumatology of the North Shore in Skokie, IL, discusses evolving treatment strategies and the use of biologic therapies in the management of psoriatic disease.
Biomarkers to Distinguish Psoriatic Arthritis Prove Elusive, Study Says
May 30th 2020

Biomarkers to Distinguish Psoriatic Arthritis Prove Elusive, Study Says

Mary Caffrey
Catching psoriatric arthritis (PsA) early has been a challenge even when the diagnosis is aided by sonography, according to the authors.
How Comorbidities Affect Costs and Costs Impact Nonadherence in RA
May 29th 2020

How Comorbidities Affect Costs and Costs Impact Nonadherence in RA

Laura Joszt, MA
For patients with rheumatoid arthritis (RA), cost can play a role in patient adherence to medication, but the presence of comorbidities does not impact cost of care for patients, according to 2 abstracts presented at the Virtual 2020 International Society for Pharmacoeconomics and Outcomes Research meeting.
Practical Insights on the Changing Spectrum of Biologic Agents for the Treatment of Patients With Psoriatic Disease
May 23rd 2020

Practical Insights on the Changing Spectrum of Biologic Agents for the Treatment of Patients With Psoriatic Disease

An Interview With Jerry Bagel, MD
Jerry Bagel, MD, director of the Psoriasis Treatment Center of New Jersey, sheds light on the clinical utility of newer classes of biologic agents in the management of psoriasis and psoriatic arthritis.
Discontinuation Rates Matter When Evaluating Biologics in RA, Analysis Finds
May 22nd 2020

Discontinuation Rates Matter When Evaluating Biologics in RA, Analysis Finds

Mary Caffrey
Incremental cost-effectiveness ratios (ICERs) must be updated to reflect the fact that some patients discontinue biologics and swap in other products, the authors concluded.
Site Logo
November 14th 2019

PROs: Which Are Important to Patients and How Successfully Are They Integrated Into Clinical Care?

Laura Joszt, MA
Although patient-reported outcomes (PROs) are increasingly being used to understand treatment effectiveness, there is still a lot unknown about what measures patients find most important. Two abstracts presented at the American College of Rheumatology’s annual meeting evaluated PROs in rheumatology and how PRO measures can be used in clinical care.
Site Logo
November 14th 2019

Treating Pain in Rheumatologic Diseases With Opioids

Laura Joszt, MA
Pain is common in patients with rheumatologic diseases, and 2 abstracts presented at the American College of Rheumatology’s annual meeting analyzed opioid use in these patients, examining patient features associated with chronic use and changing opioid use patterns in the wake of the opioid epidemic.
Site Logo
November 14th 2019

The Many Benefits of, and Barriers to, Exercise in Patients With Rheumatologic Diseases

Laura Joszt, MA
Exercise can be a potent therapy for patients with rheumatologic diseases and can result in improvements in inflammation, disease activity score, pain, stiffness, and fatigue. However, exercise needs to be modified for these patients to address the unique barriers they may have compared with the general population, said panelists during a session at the American College of Rheumatology’s annual meeting.
Site Logo
November 14th 2019

Sarilumab as a Combination or Monotherapy Successfully Targets IL-6, Improves Symptoms in Patients With RA

Laura Joszt, MA
Patients with rheumatoid arthritis (RA) not only deal with functional impairment, but also pain, fatigue, and other symptoms driven by interleukin (IL)-6 levels. In a session at the American College of Rheumatology’s annual meeting, 2 speakers examined the role of IL-6 in RA and treatment using sarilumab (Kevzara) to target and block IL-6 signals.
Site Logo
November 13th 2019

Using Technology and Virtual Reality to Improve Outcomes, Quality of Life

Laura Joszt, MA
New technologies that can monitor sleep, track itching patterns, or assist with pain are improving outcomes and quality of life for patients with rheumatologic conditions, according to panelists at the American College of Rheumatology’s annual meeting.
Site Logo
November 13th 2019

Evaluating Sarilumab's Efficacy as a Monotherapy in Rheumatoid Arthritis

Laura Joszt, MA
Monotherapy was a big topic of conversation at the American College of Rheumatology’s annual meeting, held November 8-13 in Atlanta, Georgia, and 2 abstracts highlight the efficacy of sarilumab as a monotherapy in patients with rheumatoid arthritis.
Dr Stephen Messier Discusses the Importance of Nonpharmacologic Interventions in Knee OA
November 13th 2019

Dr Stephen Messier Discusses the Importance of Nonpharmacologic Interventions in Knee OA

Since there are no cures for knee osteoarthritis (OA), exercise and weight loss remain the best first-line therapies to decrease pain and improve function, said Stephen P. Messier, PhD, professor and director of the J.B. Snow Biomechanics Laboratory at Wake Forest University.
Site Logo
November 12th 2019

Sarilumab Reduces Unacceptable Pain, Lowers Glucocorticoid Doses, and Costs Less per Responder Than Comparators

Laura Joszt, MA
Patients with rheumatoid arthritis receiving sarilumab have lower odds of unacceptable pain and are able to reduce their dose of oral glucocorticoid; they also have lower costs per responder than most other treatments, according to a trio of abstracts presented at the American College of Rheumatology/Association of Rheumatology Professionals 2019 Annual Meeting.
Dr Elaine Husni: Huge Savings With Biosimilars Have Not Manifested
November 12th 2019

Dr Elaine Husni: Huge Savings With Biosimilars Have Not Manifested

While biosimilars have brought down the cost of therapies, the savings are not quite as huge as providers may have been led to believe when biosimilars were initially under development, said Elaine Husni, MD, MPH, vice chair and director of the Arthritis and Musculoskeletal Center in the Orthopedic and Rheumatologic Institute at the Cleveland Clinic.
Dr Jeffrey Curtis Discusses Using Live Virus Vaccines in Immunocompromised Patients
November 11th 2019

Dr Jeffrey Curtis Discusses Using Live Virus Vaccines in Immunocompromised Patients

Patients with immunosuppressive conditions, particularly those being treated with tumor necrosis factor inhibitors, are vulnerable to infections, but rheumatologists have mostly been hesitant to use any live virus vaccines in these patients, said Jeffrey R. Curtis, MD, MS, MPH, professor of medicine in the Division of Clinical Immunology and Rheumatology at the University of Alabama at Birmingham.
Site Logo
November 11th 2019

Using Patient Characteristics to Predict Clinical Outcomes in RA

Laura Joszt, MA
Grouping patients into clusters based on shared characteristics, such as disease control and general health, may be helpful in understanding and predicting clinical outcomes in patients with rheumatoid arthritis (RA), according to an abstract presented at the 2019 ACR/ARP Annual Meeting, held November 8-13 in Atlanta, Georgia.
Dr Yusuf Yazici Discusses Disease Activity Assessment Tools in RA, Osteoarthritis
November 11th 2019

Dr Yusuf Yazici Discusses Disease Activity Assessment Tools in RA, Osteoarthritis

Disease activity assessments can help physicians treat to targets, but in some areas those targets have not been set yet, said Yusuf Yazici, MD, clinical associate professor in the Department of Medicine at NYU Langone Health.
Site Logo
November 10th 2019

2019 Brought Impressive Results for TNF Inhibitors, Research Into Monotherapy, Interest in CBD

Laura Joszt, MA
This year has been an exciting time for rheumatologists with impressive clinical trial results and promising outcomes for patients, said Susan Manzi, MD, MPH, codirector of the Lupus Center of Excellence and chair of the Department of Medicine of West Penn Allegheny Health System, during a session at the American College of Rheumatology annual meeting in Atlanta, Georgia.
Site Logo
September 24th 2019

Real-World Outcomes Among Patients With Early Rapidly Progressive Rheumatoid Arthritis

Andrew J. Klink, PhD, MPH Tammy G. Curtice, PharmD, MBA, MS Kiran Gupta, PhD, MPharm Kenneth W. Tuell, RPh, BCGP A. Richard Szymialis, RPh Damion Nero, PhD Bruce A. Feinberg, DO
This study suggests that lower healthcare resource use and achieving low disease activity are associated with first-line abatacept compared with a first-line tumor necrosis factor-α inhibitor for patients with early rapidly progressive rheumatoid arthritis.
<1
...
4567891011>

2 Commerce Drive
Suite 100
Cranbury, NJ 08512

© 2024 MJH Life Sciences® and AJMC®.
All rights reserved.

About
Contact
Editorial Boards
Advertise
Do Not Sell My Information
Terms & Conditions
Privacy Policy
AJMC Managed Markets Network Logo
CH LogoCenter for Biosimilars Logo